Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of anti-immunoglobulin E therapy on chronic prurigo and cholinergic urticaria
jRCTs031180092Completed
- Sponsor
- Grants-in-Aid for Scientific Research
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of omalizumab in chronic prurigo (CPG) and Cholinergic Urticaria (CU), sponsored by Grants-in-Aid for Scientific Research. Primary endpoint: skin symptom. Started Mar 2018; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic prurigo (CPG)Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on jRCTs031180092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180092.